VIP vs Enfuvirtide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Vasoactive Intestinal Peptide, Aviptadil
VIP (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. It is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for COVID-19 respiratory failure and pulmonary conditions. No VIP product is FDA-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people.
Also: Fuzeon, T-20
Enfuvirtide (brand name Fuzeon, originally T-20) is a 36-amino-acid synthetic peptide and the first HIV fusion inhibitor, FDA-approved in March 2003. It is a genuine prescription antiretroviral, not a research-only compound, and it is given as a twice-daily subcutaneous injection. Its job is narrow but important: it blocks HIV from entering a host cell in the first place, and it is reserved for people whose virus has stopped responding to other drugs.
Key Comparison Insights
- Enfuvirtide is FDA approved, while VIP remains in research stages.
- Both peptides belong to the Immune category, suggesting similar primary applications.
- Enfuvirtide has stronger research evidence (FDA Approved) compared to VIP (Human Trials).
Detailed Comparison
| Attribute | VIP | Enfuvirtide |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | VIP works through two G-protein-coupled receptors, VPAC1 and VPAC2, which are spread across immune cells, the gut, blood vessels, and the brain. When VIP binds, the receptor raises intracellular cyclic AMP, and that signal relaxes smooth muscle (so blood vessels and airways dilate) and tamps down inflammatory signaling. On the immune side, that rise in cAMP blunts NF-kB activity and lowers pro-inflammatory cytokines like TNF-alpha, which is the basis for calling VIP an endogenous anti-inflammatory. The same pathway is why researchers looked at it for the runaway lung inflammation seen in severe COVID-19. It is a broadly active hormone, not a targeted single-tissue drug, which is part of why dosing it safely is tricky. | HIV gets into a cell using a surface protein called gp41, which works like a folding grappling hook. Two stretches of that protein, called heptad repeat 1 and heptad repeat 2, snap together to pull the virus and the cell membrane close enough to fuse. Enfuvirtide is a copy of the HR2 stretch, so it slides in and binds HR1 first, jamming the hinge before it can collapse. With the hinge stuck open, the membranes never fuse and the virus is locked outside the cell. Because it acts on the outside of the cell, it works against HIV that is already resistant to drugs targeting the virus's internal machinery. |
| Common Dosing | 50-100 mcg intranasal daily 1-2x daily, intranasal | Limited community data available See research protocols |
| Administration | IV infusion, inhaled, or intranasal | Subcutaneous injection twice daily |
| Typical Duration | Variable by indication | Ongoing as part of HIV regimen |
| Best Time to Take | Morning or as directed | Morning or as directed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Most of the real human data on VIP comes from aviptadil, the synthetic analog. A randomized controlled trial of intravenous aviptadil in critically ill COVID-19 patients with respiratory failure (about 196 patients, published in Critical Care Medicine in 2022) did not hit its primary endpoint of being alive and free of respiratory failure at 60 days, though there were exploratory signals worth following up. Larger and inhaled formulations were studied through the ACTIV-3b/TESICO program, and the overall picture is mixed rather than a clear win. Beyond the lungs, VIP and its VPAC receptors are studied in rheumatoid arthritis, pulmonary arterial hypertension, and other inflammatory conditions, but that work is largely mechanistic or early-stage. There is no good human evidence supporting the anti-aging, longevity, or general wellness claims VIP is sold for online. Bottom line: a genuinely interesting immune-modulating peptide with real trials, but the trials were in serious illness and did not establish it as an effective therapy. | This is one of the better-evidenced antiretrovirals, with real randomized human trials behind it. The pivotal TORO 1 and TORO 2 phase 3 trials, published in the New England Journal of Medicine in 2003, enrolled heavily treatment-experienced patients and showed that adding enfuvirtide to an optimized background regimen roughly doubled the drop in viral load compared with the background regimen alone, with mean HIV RNA reductions on the order of 1.5 log10 copies per mL. Earlier dose-ranging work documented its subcutaneous pharmacokinetics and antiviral activity in HIV-infected adults. The main real-world drawbacks are practical, not theoretical: nearly all patients get injection-site reactions, and twice-daily injections are a burden, which is why newer oral salvage options have largely displaced it. Resistance does develop, usually through mutations in the gp41 HR1 region, so it is always used as part of a combination regimen. It remains an approved drug rather than a speculative peptide, but it is now a niche, last-resort option. |
Frequently Asked Questions: VIP vs Enfuvirtide
What is the difference between VIP and Enfuvirtide?
VIP is a immune peptide that vip (vasoactive intestinal peptide) is a 28-amino-acid signaling peptide your own gut, nerves, and immune cells make. it is a natural anti-inflammatory and a potent vasodilator, and a synthetic version called aviptadil has been tested in humans for covid-19 respiratory failure and pulmonary conditions. no vip product is fda-approved for the wellness or anti-aging uses it gets marketed for, and most of that human data is in lung disease, not in healthy people. Enfuvirtide is a immune peptide that enfuvirtide (brand name fuzeon, originally t-20) is a 36-amino-acid synthetic peptide and the first hiv fusion inhibitor, fda-approved in march 2003. it is a genuine prescription antiretroviral, not a research-only compound, and it is given as a twice-daily subcutaneous injection. its job is narrow but important: it blocks hiv from entering a host cell in the first place, and it is reserved for people whose virus has stopped responding to other drugs. The main differences lie in their mechanisms of action and clinical applications.
Which is better, VIP or Enfuvirtide?
Neither is universally "better" - the choice depends on your specific goals. VIP is typically used for immune purposes, while Enfuvirtide is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can VIP and Enfuvirtide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using VIP and Enfuvirtide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.